Pliant Therapeutics, Inc. (NASDAQ:PLRX) Insider Sells $178,483.20 in Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) insider Hans Hull sold 15,936 shares of the firm’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the sale, the insider now owns 211,558 shares in the company, valued at $2,369,449.60. The trade was a 7.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Pliant Therapeutics Price Performance

Shares of PLRX stock traded down $0.15 during midday trading on Wednesday, reaching $10.92. 700,759 shares of the company were exchanged, compared to its average volume of 454,935. The company’s 50 day moving average price is $13.24 and its two-hundred day moving average price is $13.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The company has a market cap of $664.48 million, a P/E ratio of -3.27 and a beta of 1.05. Pliant Therapeutics, Inc. has a 12 month low of $10.22 and a 12 month high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.04. On average, sell-side analysts expect that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Institutional Investors Weigh In On Pliant Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Atria Investments Inc acquired a new position in shares of Pliant Therapeutics in the 3rd quarter worth approximately $112,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of Pliant Therapeutics during the second quarter worth $126,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Pliant Therapeutics in the 3rd quarter valued at $145,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Pliant Therapeutics in the 3rd quarter valued at approximately $342,000. 97.30% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pliant Therapeutics has an average rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.